Ibio Inc (IBIO) 0.90 $IBIO
Money flow into Ibio gains momentum on pending start of U.S. Ebola vaccine trial
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 11:20AM CST
IBIO: 0.90 (+0.36)
iBio awarded protein expression technology patents in the US and Europe
M2 - Fri Feb 13, 4:53AM CST
Plant biotechnology company iBio (NYSE MKT:IBIO) reported on Thursday the receipt of additional patents in the US and Europe covering novel plant viral vector-based protein expression technologies.
IBIO: 0.90 (+0.36)
iBio Receives US and European Patents for Protein Expression Technology
Marketwired - Thu Feb 12, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, today announced the issuance of additional patents in the US and Europe covering novel plant viral vector-based protein expression technologies.
IBIO: 0.90 (+0.36)
iBio Adds to iBioModulator Portfolio and Product Pipeline
Marketwired - Wed Feb 04, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, today announced the issue of a new U.S. patent in the company's iBioModulator(TM) thermostable immunomodulator protein portfolio. The new patent, Serial No. 8,945,580 entitled "Yersinia pestis Antigens, Vaccine Compositions and Related Methods," includes claims covering plague antigens fused to the Company's iBioModulator(TM) thermostable immunomodulator protein, as well as vaccine compositions and a method for producing a protective immune response to the antigen. Scientific data previously published in the peer-reviewed scientific journal, Vaccine, demonstrated that a recombinant plague vaccine incorporating the iBioModulator(TM) thermostable immunomodulator protein, and produced via the iBioLaunch(TM) gene expression platform in green plants, provided full protection of non-human primates against aerosolized Y. pestis (pneumonic plague), a potential bioterrorism weapon.
IBIO: 0.90 (+0.36)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 391.66 (-0.45), PSTI: 2.91 (+0.01), ASPX: 65.76 (+2.76), LPTN: 2.97 (-0.01), IBIO: 0.90 (+0.36), FGEN: 30.25 (+0.50), AQXP: 10.29 (-0.54), ITMN: 73.89 (-0.02), GALT: 3.84 (+0.16), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), GILD: 101.90 (+1.10), CGEN: 8.19 (+0.08), FPRX: 24.63 (+0.63), CELGZ: 3.17 (-0.04)
Market Momentum on Biotech Stocks - CTI BioPharma, Keryx Biopharma, Intrexon, Catalyst Pharma Partners, and iBio
PR Newswire - Wed Jan 14, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corporation (NASDAQ: CTIC), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Intrexon Corporation (NYSE: XON), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX), and iBio Inc. (NYSE MKT: IBIO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, January 13, 2015, ended on a negative note as the Dow Jones Industrial Average finished at 17,613.68, down 0.15% and the NASDAQ Composite closed at 4,661.50, down 0.07%. The S&P 500 finished the session 0.26% lower at 2,023.03. During the trading session, eight out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 808.73, down 0.49%, whereas the index has gained 13.71% in the previous three months. Register for your complimentary reports on these five stocks at:
CPRX: 3.36 (-0.10), XON: 39.30 (+1.05), IBIO: 0.90 (+0.36), CTIC: 2.23 (-0.02), KERX: 11.63 (-0.60)
Biotech Weekly: Lessons Learned From Investing In Ebola Stocks
Daniel Ward - at Seeking Alpha - Mon Jan 12, 7:38AM CST
HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), IBIO: 0.90 (+0.36)
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.84 (-0.01), PFNX: 12.45 (+0.29), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), RPTP: 9.05 (-0.40), IBIO: 0.90 (+0.36), ANAC: 40.76 (-0.07), PFE: 34.64 (-0.23), GNCA: 8.93 (-0.07), GSK: 47.94 (+1.99), AZN: 69.96 (+0.20), NVS: 102.20 (-0.17)
Hagens Berman Reminds Investors of the Upcoming Lead Plaintiff Deadline of December 23, 2014 in the Class Action Lawsuit Against iBio, Inc. (NYSE MKT: IBIO)
GlobeNewswire - Tue Dec 16, 7:37AM CST
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, reminds investors that they have until December 23, 2014 to move for lead plaintiff in the lawsuit against iBio, Inc. (NYSE MKT:IBIO) ("iBio" or "the Company"
The suit is pending in U.S. District Court for the District of Delaware.
IBIO: 0.90 (+0.36)
IBIO SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against iBio, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 23, 2014 -- IBIO
GlobeNewswire - Mon Dec 15, 10:51AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased iBio, Inc. ("iBio" or the "Company" (NYSE MKT:IBIO) securities between October 13, 2014 and October 23, 2014.
IBIO: 0.90 (+0.36)
EQUITY ALERT: Rosen Law Firm Reminds iBio, Inc. Investors of Important December 23, 2014 Deadline in Class Action Filed by the Firm - IBIO
GlobeNewswire - Thu Dec 11, 5:02PM CST
Rosen Law Firm reminds purchasers of iBio, Inc. common stock (NYSE MKT:IBIO) between October 13, 2014 and October 23, 2014, inclusive of the important December 23, 2014 lead plaintiff deadline in the class action filed by the firm.
IBIO: 0.90 (+0.36)
iBio Provides Updates on Its IBIO-CFB03 Fibrosis Drug Candidate and Other Activities for the 2014 Annual Shareholders Meeting
Marketwired - Wed Dec 10, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in biotechnology for developing and manufacturing plant-made pharmaceutical products, will provide shareholders and attendees at its Annual Meeting today with an update on current activities including progress in developing IBIO-CFB03 to address significant unmet medical need for the treatment of idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and other fibrotic diseases.
IBIO: 0.90 (+0.36)
Biotech Weekly: Everything You Want To Know About Small Cap Biotech Cult Stocks
Daniel Ward - at Seeking Alpha - Mon Dec 08, 10:35AM CST
HEB: 0.25 (+0.01), IBIO: 0.90 (+0.36), MNKD: 7.00 (+0.02), ARNA: 4.55 (+0.02)
Technical Scrutiny on Biotech Stocks - CTI BioPharma, Vertex Pharma, Progenics Pharma, iBio, and NewLink Genetics
PR Newswire - Tue Dec 02, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corporation (NASDAQ: CTIC), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), iBio Inc. (NYSE MKT: IBIO), and NewLink Genetics Corporation (NASDAQ: NLNK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, December 01, 2014, the NASDAQ Composite ended at 4,727.35, down 1.34%, the Dow Jones Industrial Average edged 0.29% lower, to finish the day at 17,776.80, and the S&P 500 closed at 2,053.44, down 0.68%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 802.07, down 0.20%, while the index has advanced 8.74% in the previous three months. Register for your complimentary reports on these five stocks at:
PGNX: 5.66 (+0.06), VRTX: 113.66 (+4.03), NLNK: 38.84 (+1.51), IBIO: 0.90 (+0.36), CTIC: 2.23 (-0.02)
IBIO SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against iBio, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 23, 2014 -- IBIO
PR Newswire - Mon Dec 01, 11:22AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased iBio, Inc. ("iBio" or the "Company" (NYSE MKT: IBIO) securities between October 13, 2014 and October 23, 2014.
IBIO: 0.90 (+0.36)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in iBio, Inc. (IBIO) to Contact the Firm
GlobeNewswire - Fri Nov 21, 6:40PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in iBio, Inc. ("iBio" or the "Company" (NYSE:IBIO) of the December 23, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against iBio and the Company's CEO.
IBIO: 0.90 (+0.36)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in iBio, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit -- IBIO
GlobeNewswire - Wed Nov 19, 8:28PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of purchasers of iBio, Inc. ("iBio" or the "Company" (NYSE:IBIO) common stock during the period between October 13, 2014 and October 23, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until December 23, 2014 to seek appointment as lead plaintiff.
IBIO: 0.90 (+0.36)
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene
PR Newswire - Fri Nov 14, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), iBio Inc. (NYSE MKT: IBIO), and Celgene Corporation (NASDAQ: CELG). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, November 13, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,652.79, up 0.23% and the NASDAQ Composite closed at 4,680.14, up 0.11%. The S&P 500 finished the session 0.05% higher at 2,039.33. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.78, down 0.10%, whereas the index has gained 10.85% in the previous three months. Register for your complimentary reports on these five stocks at:
GILD: 101.90 (+1.10), IBIO: 0.90 (+0.36), ARIA: 7.35 (+0.45), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16)
Morgan & Morgan Reminds Investors That a Class Action Lawsuit Has Been Filed Against iBio, Inc. -- IBIO
GlobeNewswire - Thu Nov 13, 1:35PM CST
Morgan & Morgan reminds investors that a class action has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased iBio, Inc. ("iBio" or the "Company" (NYSE:IBIO) securities between October 13, 2014 and October 23, 2014.
IBIO: 0.90 (+0.36)
Money flow into Ibio gains momentum on pending start of U.S. Ebola vaccine trial
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 11:20AM CST
IBIO: 0.90 (+0.36)
iBio awarded protein expression technology patents in the US and Europe
M2 - Fri Feb 13, 4:53AM CST
Plant biotechnology company iBio (NYSE MKT:IBIO) reported on Thursday the receipt of additional patents in the US and Europe covering novel plant viral vector-based protein expression technologies.
IBIO: 0.90 (+0.36)
iBio Receives US and European Patents for Protein Expression Technology
Marketwired - Thu Feb 12, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, today announced the issuance of additional patents in the US and Europe covering novel plant viral vector-based protein expression technologies.
IBIO: 0.90 (+0.36)
iBio Adds to iBioModulator Portfolio and Product Pipeline
Marketwired - Wed Feb 04, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, today announced the issue of a new U.S. patent in the company's iBioModulator(TM) thermostable immunomodulator protein portfolio. The new patent, Serial No. 8,945,580 entitled "Yersinia pestis Antigens, Vaccine Compositions and Related Methods," includes claims covering plague antigens fused to the Company's iBioModulator(TM) thermostable immunomodulator protein, as well as vaccine compositions and a method for producing a protective immune response to the antigen. Scientific data previously published in the peer-reviewed scientific journal, Vaccine, demonstrated that a recombinant plague vaccine incorporating the iBioModulator(TM) thermostable immunomodulator protein, and produced via the iBioLaunch(TM) gene expression platform in green plants, provided full protection of non-human primates against aerosolized Y. pestis (pneumonic plague), a potential bioterrorism weapon.
IBIO: 0.90 (+0.36)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 391.66 (-0.45), PSTI: 2.91 (+0.01), ASPX: 65.76 (+2.76), LPTN: 2.97 (-0.01), IBIO: 0.90 (+0.36), FGEN: 30.25 (+0.50), AQXP: 10.29 (-0.54), ITMN: 73.89 (-0.02), GALT: 3.84 (+0.16), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), GILD: 101.90 (+1.10), CGEN: 8.19 (+0.08), FPRX: 24.63 (+0.63), CELGZ: 3.17 (-0.04)
Market Momentum on Biotech Stocks - CTI BioPharma, Keryx Biopharma, Intrexon, Catalyst Pharma Partners, and iBio
PR Newswire - Wed Jan 14, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corporation (NASDAQ: CTIC), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Intrexon Corporation (NYSE: XON), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX), and iBio Inc. (NYSE MKT: IBIO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, January 13, 2015, ended on a negative note as the Dow Jones Industrial Average finished at 17,613.68, down 0.15% and the NASDAQ Composite closed at 4,661.50, down 0.07%. The S&P 500 finished the session 0.26% lower at 2,023.03. During the trading session, eight out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 808.73, down 0.49%, whereas the index has gained 13.71% in the previous three months. Register for your complimentary reports on these five stocks at:
CPRX: 3.36 (-0.10), XON: 39.30 (+1.05), IBIO: 0.90 (+0.36), CTIC: 2.23 (-0.02), KERX: 11.63 (-0.60)
Biotech Weekly: Lessons Learned From Investing In Ebola Stocks
Daniel Ward - at Seeking Alpha - Mon Jan 12, 7:38AM CST
HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), IBIO: 0.90 (+0.36)
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.84 (-0.01), PFNX: 12.45 (+0.29), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), RPTP: 9.05 (-0.40), IBIO: 0.90 (+0.36), ANAC: 40.76 (-0.07), PFE: 34.64 (-0.23), GNCA: 8.93 (-0.07), GSK: 47.94 (+1.99), AZN: 69.96 (+0.20), NVS: 102.20 (-0.17)
Hagens Berman Reminds Investors of the Upcoming Lead Plaintiff Deadline of December 23, 2014 in the Class Action Lawsuit Against iBio, Inc. (NYSE MKT: IBIO)
GlobeNewswire - Tue Dec 16, 7:37AM CST
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, reminds investors that they have until December 23, 2014 to move for lead plaintiff in the lawsuit against iBio, Inc. (NYSE MKT:IBIO) ("iBio" or "the Company"
The suit is pending in U.S. District Court for the District of Delaware. IBIO: 0.90 (+0.36)
IBIO SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against iBio, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 23, 2014 -- IBIO
GlobeNewswire - Mon Dec 15, 10:51AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased iBio, Inc. ("iBio" or the "Company"
(NYSE MKT:IBIO) securities between October 13, 2014 and October 23, 2014. IBIO: 0.90 (+0.36)
EQUITY ALERT: Rosen Law Firm Reminds iBio, Inc. Investors of Important December 23, 2014 Deadline in Class Action Filed by the Firm - IBIO
GlobeNewswire - Thu Dec 11, 5:02PM CST
Rosen Law Firm reminds purchasers of iBio, Inc. common stock (NYSE MKT:IBIO) between October 13, 2014 and October 23, 2014, inclusive of the important December 23, 2014 lead plaintiff deadline in the class action filed by the firm.
IBIO: 0.90 (+0.36)
iBio Provides Updates on Its IBIO-CFB03 Fibrosis Drug Candidate and Other Activities for the 2014 Annual Shareholders Meeting
Marketwired - Wed Dec 10, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in biotechnology for developing and manufacturing plant-made pharmaceutical products, will provide shareholders and attendees at its Annual Meeting today with an update on current activities including progress in developing IBIO-CFB03 to address significant unmet medical need for the treatment of idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and other fibrotic diseases.
IBIO: 0.90 (+0.36)
Biotech Weekly: Everything You Want To Know About Small Cap Biotech Cult Stocks
Daniel Ward - at Seeking Alpha - Mon Dec 08, 10:35AM CST
HEB: 0.25 (+0.01), IBIO: 0.90 (+0.36), MNKD: 7.00 (+0.02), ARNA: 4.55 (+0.02)
Technical Scrutiny on Biotech Stocks - CTI BioPharma, Vertex Pharma, Progenics Pharma, iBio, and NewLink Genetics
PR Newswire - Tue Dec 02, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corporation (NASDAQ: CTIC), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), iBio Inc. (NYSE MKT: IBIO), and NewLink Genetics Corporation (NASDAQ: NLNK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, December 01, 2014, the NASDAQ Composite ended at 4,727.35, down 1.34%, the Dow Jones Industrial Average edged 0.29% lower, to finish the day at 17,776.80, and the S&P 500 closed at 2,053.44, down 0.68%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 802.07, down 0.20%, while the index has advanced 8.74% in the previous three months. Register for your complimentary reports on these five stocks at:
PGNX: 5.66 (+0.06), VRTX: 113.66 (+4.03), NLNK: 38.84 (+1.51), IBIO: 0.90 (+0.36), CTIC: 2.23 (-0.02)
IBIO SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against iBio, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 23, 2014 -- IBIO
PR Newswire - Mon Dec 01, 11:22AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased iBio, Inc. ("iBio" or the "Company"
(NYSE MKT: IBIO) securities between October 13, 2014 and October 23, 2014. IBIO: 0.90 (+0.36)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in iBio, Inc. (IBIO) to Contact the Firm
GlobeNewswire - Fri Nov 21, 6:40PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in iBio, Inc. ("iBio" or the "Company"
(NYSE:IBIO) of the December 23, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against iBio and the Company's CEO. IBIO: 0.90 (+0.36)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in iBio, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit -- IBIO
GlobeNewswire - Wed Nov 19, 8:28PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of purchasers of iBio, Inc. ("iBio" or the "Company"
(NYSE:IBIO) common stock during the period between October 13, 2014 and October 23, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until December 23, 2014 to seek appointment as lead plaintiff. IBIO: 0.90 (+0.36)
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene
PR Newswire - Fri Nov 14, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), iBio Inc. (NYSE MKT: IBIO), and Celgene Corporation (NASDAQ: CELG). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, November 13, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,652.79, up 0.23% and the NASDAQ Composite closed at 4,680.14, up 0.11%. The S&P 500 finished the session 0.05% higher at 2,039.33. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.78, down 0.10%, whereas the index has gained 10.85% in the previous three months. Register for your complimentary reports on these five stocks at:
GILD: 101.90 (+1.10), IBIO: 0.90 (+0.36), ARIA: 7.35 (+0.45), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16)
Morgan & Morgan Reminds Investors That a Class Action Lawsuit Has Been Filed Against iBio, Inc. -- IBIO
GlobeNewswire - Thu Nov 13, 1:35PM CST
Morgan & Morgan reminds investors that a class action has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased iBio, Inc. ("iBio" or the "Company"
(NYSE:IBIO) securities between October 13, 2014 and October 23, 2014. IBIO: 0.90 (+0.36)
